NASDAQ NMS - GLOBAL MARKET · AVLN
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Avalyn Pharma Inc

Avalyn Pharma Inc

Pharmaceuticals
$37.69
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Earnings absence reason unknown
AVLN
Avalyn Pharma Inc
Mon Aug 24 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

65/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Mon Aug 24 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is AVLN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading AVLN catalysts
About Avalyn Pharma Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2026
Country
US

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$37.69
Last session
Day high
$37.69
Last session
Day low
$37.69
Last session
Previous close
$37.69
52W high
$39.25
-3.97% from high
52W low
$25.68
89% of range
Market cap
$1.7B
EPS
$-3.9200
Beta
-0.04
Shares out
44.3M
Avg volume
198.4K
VWAP
$37.69
Last session
Price history computed in-house
1W
-3.01%
1M
+34.85%
3M
+40.53%
SMA 50 $31.24 · above
SMA 200 Not reported · Not reported
52W position 89%

AVLN overview

Veridion Score
65
Registered · 2026-08-24
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around AVLN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading AVLN Form 4 filings
Public disclosures

Congress activity in AVLN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for AVLN in the cached public ledger.

Federal contracts

AVLN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AVLN in this window.
Lobbying spend

AVLN lobbying filings, year to date.

Registered lobbying filings matched to Avalyn Pharma Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AVLN in this window.
Loading news for AVLN
Analyst ratings
Sovereign unlock shows live analyst consensus for AVLN.
Options
Sovereign unlock shows live options positioning for AVLN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.